MIM
VXRT

MetLife Investment Management’s Vaxart VXRT Stock Holding History

MetLife Investment Management’s Portfolio VXRT Stock Details VXRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-66,887
Closed -$64.3K – 2817
2022
Q4 		$64.3K Hold
66,887
– – ﹤0.01% 2724
2022
Q3 		$146K Buy
66,887
+23,981
+56% +$82.7K ﹤0.01% 2476
2022
Q2 		$150K Sell
42,906
-25,801
-38% -$96.4K ﹤0.01% 2492
2022
Q1 		$346K Buy
68,707
+24,690
+56% +$125K ﹤0.01% 2005
2021
Q4 		$276K Buy
44,017
+9,268
+27% +$63.3K ﹤0.01% 1853
2021
Q3 		$276K Sell
34,749
-9,990
-22% -$82.2K ﹤0.01% 1878
2021
Q2 		$335K Buy
44,739
+39,182
+705% +$274K ﹤0.01% 1816
2021
Q1 		$33.6K Sell
5,557
-18,441
-77% -$142K ﹤0.01% 2292
2020
Q4 		$137K Buy
23,998
+1,716
+8% +$10.9K ﹤0.01% 2163
2020
Q3 		$148K Hold
22,282
– – ﹤0.01% 2029
2020
Q2 		$197K Buy
+22,282
New +$64K ﹤0.01% 1915

Other funds holding VXRT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MetLife Investment Management's VXRT Position: Q1 2023 in Review

MetLife Investment Management sold out of Vaxart (VXRT) in Q1 2023, closing a stake of 66,887 shares — an estimated $64.3K sold.

MetLife Investment Management first reported a position in VXRT in Q2 2020 and held it in 11 quarters. The position peaked at $346K in Q1 2022. 109 funds tracked by Wall St. Rank hold VXRT as of Q1 2023.

  • MetLife Investment Management reported no remaining Vaxart position as of Q1 2023 after selling out during the quarter.
  • MetLife Investment Management sold 66,887 Vaxart shares in Q1 2023, an estimated $64.3K.
  • MetLife Investment Management first reported a position in Vaxart in Q2 2020 and held it in 11 quarters.
  • MetLife Investment Management's Vaxart position peaked at $346K in Q1 2022.
  • 109 funds tracked by Wall St. Rank held Vaxart as of Q1 2023.

Based on MetLife Investment Management's 13F filing for Q1 2023, filed 15 May 2023.